Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
Revance provided a corporate update and reported its third quarter 2024 financial results. Key highlights include:
Merger Agreement: Revance and Crown Laboratories entered into a merger agreement, with Crown offering $6.66 per share for all outstanding Revance shares. The tender offer deadline was extended to November 12, 2024.
Distribution Agreements: Revance amended its agreement with Teoxane for U.S. distribution of RHA® dermal fillers and signed a new exclusive agreement for DAXXIFY® distribution in Australia and New Zealand.
China Approval: DAXXIFY was approved in China for improving glabellar lines.
Financials: Q3 2024 net revenue was $59.9 million, up 11% from Q3 2023. However, the company reported a net loss of $38.1 million. SG&A expenses decreased to $62.6 million, and R&D expenses were $11.4 million.
Guidance Withdrawn: Revance withdrew its 2024 financial guidance and will not hold a conference call for Q3 results.
Revance ha fornito un aggiornamento aziendale e ha riportato i suoi risultati finanziari del terzo trimestre 2024. I punti salienti includono:
Accordo di Fusione: Revance e Crown Laboratories hanno stipulato un accordo di fusione, con Crown che offre 6,66 dollari per azione per tutte le azioni in circolazione di Revance. La scadenza per l'offerta pubblica è stata estesa al 12 novembre 2024.
Accordi di Distribuzione: Revance ha modificato il suo accordo con Teoxane per la distribuzione negli Stati Uniti dei riempitivi dermici RHA® e ha firmato un nuovo accordo esclusivo per la distribuzione di DAXXIFY® in Australia e Nuova Zelanda.
Approvazione in Cina: DAXXIFY è stato approvato in Cina per il trattamento delle linee glabellari.
Finanziari: I ricavi netti del terzo trimestre 2024 sono stati di 59,9 milioni di dollari, in aumento dell'11% rispetto al terzo trimestre 2023. Tuttavia, l'azienda ha riportato una perdita netta di 38,1 milioni di dollari. Le spese SG&A sono diminuite a 62,6 milioni di dollari, e le spese di R&D sono state di 11,4 milioni di dollari.
Previsioni Ritirate: Revance ha ritirato le previsioni finanziarie per il 2024 e non terrà una conferenza telefonica per i risultati del terzo trimestre.
Revance proporcionó una actualización corporativa y reportó sus resultados financieros del tercer trimestre de 2024. Los aspectos más destacados incluyen:
Acuerdo de Fusión: Revance y Crown Laboratories firmaron un acuerdo de fusión, con Crown ofreciendo 6,66 dólares por acción por todas las acciones en circulación de Revance. La fecha límite de la oferta se extendió hasta el 12 de noviembre de 2024.
Acuerdos de Distribución: Revance modificó su acuerdo con Teoxane para la distribución en EE. UU. de los rellenos dérmicos RHA® y firmó un nuevo acuerdo exclusivo para la distribución de DAXXIFY® en Australia y Nueva Zelanda.
Aprobación en China: DAXXIFY fue aprobado en China para mejorar las líneas glabelares.
Financieros: Los ingresos netos del tercer trimestre de 2024 fueron de 59,9 millones de dólares, un aumento del 11% con respecto al tercer trimestre de 2023. Sin embargo, la empresa reportó una pérdida neta de 38,1 millones de dólares. Los gastos SG&A disminuyeron a 62,6 millones de dólares, y los gastos de I+D fueron de 11,4 millones de dólares.
Guía Retirada: Revance retiró su guía financiera para 2024 y no llevará a cabo una llamada de conferencia para los resultados del tercer trimestre.
Revance는 기업 업데이트를 제공하였고 2024년 3분기 재무 결과를 보고했습니다. 주요 내용은 다음과 같습니다:
합병 계약: Revance와 Crown Laboratories가 합병 계약을 체결하였으며, Crown은 Revance의 모든 발행 주식에 대해 주당 6.66달러를 제안했습니다. 입찰 마감일은 2024년 11월 12일로 연장되었습니다.
배급 계약: Revance는 RHA® 피부 필러의 미국 배급을 위해 Teoxane과의 계약을 수정하였고, 호주 및 뉴질랜드에서 DAXXIFY® 배급을 위한 새로운 독점 계약을 체결했습니다.
중국 승인: DAXXIFY는 중국에서 미간 주름 개선을 위해 승인되었습니다.
재무: 2024년 3분기 순수익은 5,990만 달러로, 2023년 3분기 대비 11% 증가했습니다. 그러나 회사는 3,810만 달러의 순손실을 보고했습니다. SG&A 비용은 6,260만 달러로 감소했으며, R&D 비용은 1,140만 달러였습니다.
지침 철회: Revance는 2024년 재무 지침을 철회하였고 3분기 결과를 위한 컨퍼런스 콜을 개최하지 않을 것입니다.
Revance a fourni une mise à jour de l'entreprise et a rapporté ses résultats financiers du troisième trimestre 2024. Les moments forts comprennent :
Accord de Fusion : Revance et Crown Laboratories ont conclu un accord de fusion, Crown proposant 6,66 $ par action pour toutes les actions en circulation de Revance. La date limite de l'offre d'achat a été prolongée jusqu'au 12 novembre 2024.
Accords de Distribution : Revance a modifié son accord avec Teoxane pour la distribution aux États-Unis des remplisseurs dermiques RHA® et a signé un nouvel accord exclusif pour la distribution de DAXXIFY® en Australie et en Nouvelle-Zélande.
Approbation en Chine : DAXXIFY a été approuvé en Chine pour améliorer les rides glabellaires.
Financiers : Les revenus nets du troisième trimestre 2024 s'élevaient à 59,9 millions de dollars, en augmentation de 11 % par rapport au troisième trimestre 2023. Cependant, l'entreprise a rapporté une perte nette de 38,1 millions de dollars. Les dépenses SG&A ont diminué à 62,6 millions de dollars, et les dépenses de R&D s'élevaient à 11,4 millions de dollars.
Prévisions Retirées : Revance a retiré ses prévisions financières pour 2024 et ne tiendra pas de conférence téléphonique pour les résultats du troisième trimestre.
Revance hat ein Unternehmensupdate gegeben und seine Finanzergebnisse für das dritte Quartal 2024 berichtet. Die wichtigsten Punkte umfassen:
Fusionsvereinbarung: Revance und Crown Laboratories haben eine Fusionsvereinbarung getroffen, wobei Crown 6,66 Dollar pro Aktie für alle ausstehenden Revance-Aktien anbietet. Die Frist für das Übernahmeangebot wurde bis zum 12. November 2024 verlängert.
Vertriebsvereinbarungen: Revance hat die Vereinbarung mit Teoxane für die US-Verteilung der RHA®-Dermal-Filler geändert und eine neue exklusive Vereinbarung für die DAXXIFY®-Verteilung in Australien und Neuseeland unterzeichnet.
Genehmigung in China: DAXXIFY wurde in China zur Verbesserung von Glabellarfalten genehmigt.
Finanzen: Der Nettoumsatz im dritten Quartal 2024 betrug 59,9 Millionen Dollar, was einem Anstieg von 11 % im Vergleich zum dritten Quartal 2023 entspricht. Das Unternehmen berichtete jedoch von einem Nettverlust von 38,1 Millionen Dollar. Die SG&A-Ausgaben sanken auf 62,6 Millionen Dollar, und die F&E-Ausgaben betrugen 11,4 Millionen Dollar.
Rücknahme der Prognose: Revance hat seine finanzielle Prognose für 2024 zurückgezogen und wird keine Telefonkonferenz für die Ergebnisse des dritten Quartals abhalten.
- Q3 2024 net revenue increased by 11% to $59.9 million.
- SG&A expenses decreased to $62.6 million for Q3 2024.
- R&D expenses decreased to $11.4 million for Q3 2024.
- DAXXIFY approved in China for glabellar lines.
- Revance reported a net loss of $38.1 million for Q3 2024.
- Revance withdrew its 2024 financial guidance.
- No conference call to discuss Q3 results.
- On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the deadline upon which the tender offer must commence to November 12, 2024. The tender offer has not yet commenced.
- Revance entered into an amendment to the Exclusive Distribution Agreement with Teoxane for the distribution of the RHA® Collection of dermal fillers in the
- Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. announced China’s National Medical Products Association’s approval of DAXXIFY in Mainland China for the temporary improvement of the appearance of moderate to severe glabellar lines.
- Revance is withdrawing the Company’s 2024 financial guidance and will not be holding a conference call to accompany its 3Q’24 financial results.
Third Quarter Highlights and Subsequent Updates
-
Crown Laboratories and Revance Announce Entry Into Merger Agreement and Delay of Tender Offer Commencement. During the quarter, Revance and Crown Laboratories, Inc (“Crown”) announced that they had entered into a merger agreement pursuant to which the companies would seek to merge the two complementary organizations. Under the terms of the agreement, which was unanimously approved by Revance's Board of Directors, Crown will commence a tender offer to purchase all of Revance’s outstanding shares of common stock, at a price of
per share, in cash. As a result of discussions between the Company and Teoxane SA (“Teoxane”) regarding an alleged breach of the Exclusive Distribution Agreement for the distribution of the RHA® Collection of dermal fillers in the$6.66 U.S. (the “U.S. Distribution Agreement”), the parties extended the date by which the tender offer must be commenced. Revance and Crown agreed to extend the tender offer commencement date to November 12, 2024 or another date mutually agreed to between the parties. -
Revance and Teoxane Enter into Agreements to Further their Partnership. Following a notice from Teoxane to remedy alleged material breaches of the
U.S. Distribution Agreement and discussions between the parties, on October 24, 2024, Revance and Teoxane entered into a sixth amendment to theU.S. Distribution Agreement and an exclusive distribution agreement (the “ANZ Distribution Agreement”) pursuant to which Teoxane will act as Revance’s and Revance Australia's exclusive distributor and licensee inAustralia and New Zealand of certain products containing DaxibotulinumtoxinA-lanm, including DAXXIFY®, for the treatment of (a) temporary improvements in the appearance of glabellar lines and other indications related to altering cosmetic appearance and (b) cervical dystonia. The ANZ Distribution Agreement expires December 31, 2040. - DAXXIFY Approved in Mainland China for Glabellar Lines. On September 9, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“Fosun”) announced that the Biologics License Application for DAXXIFY had been recently approved by China’s National Medical Products Administration for the temporary improvement in the appearance of moderate to severe glabellar lines.
Financial Highlights
-
Total net revenue for the third quarter ended September 30, 2024 was
compared to$59.9 million for the same period in 2023, representing an increase of$54.1 million 11% , due primarily to an overall increase in the sales volume of DAXXIFY and the RHA® Collection, partially offset by an overall reduction in the average selling prices for both product lines. Net revenue for the third quarter ended September 30, 2024 included of RHA® Collection revenue,$30.5 million of DAXXIFY revenue, and$28.3 million of collaboration revenue. Total net revenue for the nine months ended September 30, 2024 was$1.1 million compared to$177.2 million for the same period in 2023.$154.3 million -
Selling, general and administrative (SG&A) expenses for the three and nine months ended September 30, 2024 were
and$62.6 million compared to$197.3 million and$65.8 million , respectively, for the same periods in 2023. The decrease was primarily due to lower stock-based compensation charges and sales and marketing expenses related to DAXXIFY and the RHA® Collection, offset primarily by expenses related to the launch of DAXXIFY for cervical dystonia and$202.5 million of transaction costs related to the pending merger.$7.3 million -
Research and development (R&D) expenses for the three and nine months ended September 30, 2024 were
and$11.4 million compared to$41.7 million and$8.7 million , respectively, for the same periods in 2023. The decrease was primarily due to the$43.8 million U.S. Food and Drug Administration’s approval of our manufacturing partner’s, Ajinomoto Bio-Pharma Services, site in late Q1 2023 which allowed the subsequent DAXXIFY manufacturing expenses to be capitalized as inventory. -
Total operating expenses for the three and nine months ended September 30, 2024 were
and$92.1 million compared to$290.8 million and$91.7 million , respectively, for the same periods in 2023.$294.9 million -
Net loss from continuing operations for the three and nine months ended September 30, 2024 were
and$38.1 million , respectively, compared to$125.1 million and$39.4 million for the same periods in 2023.$146.1 million -
Cash, cash equivalents and short-term investments as of September 30, 2024 were
.$184.1 million
Note: In connection with the exit of the Fintech Platform business (HintMD and OPUL®), the results of the Fintech Platform business are reflected as discontinued operations in our financial statements as of September 30, 2024 and December 31, 2023 and for the periods ended September 30, 2024 and 2023. Therefore, the results discussed reflect our continuing operations and exclude results of the Fintech Platform, which was presented in our financial statements as the service segment.
2024 Financial Outlook
In light of the proposed merger with Crown and other recent developments, Revance will not be providing any forward-looking guidance and is withdrawing any previously provided guidance and outlook. In addition, Revance will not hold a conference call to discuss its third quarter 2024 earnings.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers, which RHA® technology is proprietary to and manufactured by Teoxane SA in
Revance’s global headquarters and experience center is located in
“Revance”, the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
Forward-Looking Statements
Any statements in this press release that are not statements of historical fact, including statements related to expectations with respect to the tender offer and the merger, including the timing thereof and the likelihood of the tender offer being commenced on the same terms as previously announced, or at all; our and Crown's ability to successfully complete the merger; the impact to the Company if the merger is not completed; plans regarding 2024 guidance; the potential to set a new standard in healthcare; patient outcomes and physician experiences; commercialization of DAXXIFY in
Forward-looking statements are subject to risks and uncertainties that could cause actual results and the timing of events to differ materially from our expectations. These risks and uncertainties relate to, but are not limited to: the risks and uncertainties inherent in the tender offer and the merger, including, among other things, regarding how many of the Company stockholders will tender their shares in the offer, the possibility that competing offers will be made, the ability to satisfy the conditions to the closing of the tender offer and the merger, the expected timing of the tender offer and the merger, the possibility that the merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties’ operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the announcement of the tender offer and the merger on the Company’s and Crown’s business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of the Company and Crown, and other circumstances beyond the Company’s and Crown’s control; our ability to obtain funding for our operations; the timing of capital expenditures; the accuracy of our estimates regarding expenses, revenues, capital requirements, supply chain and operational efficiencies; our financial performance and the economics of DAXXIFY and the RHA® Collection of dermal fillers; our ability to comply with our debt obligations; the impact of macroeconomic factors on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, regulatory meetings, inspections and approvals, clinical trials and other aspects of our business and on the market; our ability to maintain approval of our products; our ability and the ability of our partners to manufacture supplies for DAXXIFY and our drug product candidates; our ability to acquire supplies of the RHA® Collection of dermal fillers; the uncertain clinical development process; our ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to our drug product candidates and third-party manufacturers; the risk that clinical trials may not have an effective design or generate positive results or that positive results would assure regulatory approval or commercial success; the applicability of clinical study results to actual outcomes; the rate and degree of economic benefit, safety, efficacy, duration, commercial acceptance, market, competition and/or size and growth potential of DAXXIFY, the RHA® Collection of dermal fillers, and our drug product candidates, if approved; our ability to successfully commercialize DAXXIFY and to continue to successfully commercialize the RHA® Collection of dermal fillers; the timing and cost of commercialization activities; securing or maintaining adequate coverage or reimbursement by third-party payers for DAXXIFY; the proper training and administration of our products by physicians and medical staff; our ability to maintain and gain acceptance from injectors and physicians in the use of DAXXIFY for aesthetic and therapeutic indications; our ability to strengthen professional partnerships; our ability to expand sales and marketing capabilities; the status of commercial collaborations; changes in and failures to comply with laws and regulations; our ability to continue obtaining and maintaining intellectual property protection for our products; the cost and our ability to defend ourselves in product liability, intellectual property, class action or other lawsuits; our ability to limit or mitigate cybersecurity incidents; the volatility of our stock price; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the Securities and Exchange Commission (SEC), including factors described in the section entitled "Risk Factors" in our Form 10-K filed with the SEC on February 28, 2024, and including, without limitation, our Form 10-Q for the quarter ended September 30, 2024 expected to be filed with the SEC on November 7, 2024. The forward-looking statements in this press release speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
REVANCE THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) |
|||||||
|
September 30, |
|
December 31, |
||||
|
|
2024 |
|
|
|
2023 |
|
ASSETS |
|||||||
CURRENT ASSETS |
|
|
|
||||
Cash and cash equivalents |
$ |
58,585 |
|
|
$ |
137,329 |
|
Restricted cash, current |
|
465 |
|
|
|
550 |
|
Short-term investments |
|
125,491 |
|
|
|
116,586 |
|
Accounts receivable, net |
|
48,263 |
|
|
|
27,660 |
|
Inventories |
|
85,213 |
|
|
|
45,579 |
|
Prepaid expenses and other current assets |
|
9,935 |
|
|
|
9,308 |
|
Current assets of discontinued operations |
|
1,735 |
|
|
|
1,853 |
|
Total current assets |
|
329,687 |
|
|
|
338,865 |
|
Property and equipment, net |
|
15,897 |
|
|
|
17,225 |
|
Intangible assets, net |
|
7,634 |
|
|
|
9,270 |
|
Operating lease right-of-use assets |
|
47,996 |
|
|
|
53,167 |
|
Finance lease right-of-use asset |
|
13,100 |
|
|
|
19,815 |
|
Restricted cash, non-current |
|
5,564 |
|
|
|
5,995 |
|
Finance lease prepaid expense |
|
41,514 |
|
|
|
32,383 |
|
Other non-current assets |
|
172 |
|
|
|
321 |
|
Non-current assets of discontinued operations |
|
— |
|
|
|
1,413 |
|
TOTAL ASSETS |
$ |
461,564 |
|
|
$ |
478,454 |
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|||||||
CURRENT LIABILITIES |
|
|
|
||||
Accounts payable |
$ |
12,335 |
|
|
$ |
13,554 |
|
Accruals and other current liabilities |
|
34,022 |
|
|
|
52,863 |
|
Deferred revenue, current |
|
6,329 |
|
|
|
10,737 |
|
Operating lease liabilities, current |
|
6,372 |
|
|
|
5,703 |
|
Finance lease liability, current |
|
10,841 |
|
|
|
2,651 |
|
Debt, current |
|
10,150 |
|
|
|
2,500 |
|
Current liabilities of discontinued operations |
|
— |
|
|
|
1,216 |
|
Total current liabilities |
|
80,049 |
|
|
|
89,224 |
|
Debt, non-current |
|
421,041 |
|
|
|
426,595 |
|
Deferred revenue, non-current |
|
85,550 |
|
|
|
70,419 |
|
Operating lease liabilities, non-current |
|
35,043 |
|
|
|
40,985 |
|
Other non-current liabilities |
|
2,911 |
|
|
|
2,835 |
|
TOTAL LIABILITIES |
|
624,594 |
|
|
|
630,058 |
|
STOCKHOLDERS’ DEFICIT |
|
|
|
||||
Preferred stock, par value |
|
— |
|
|
|
— |
|
Common stock, par value |
|
105 |
|
|
|
88 |
|
Additional paid-in capital |
|
2,043,893 |
|
|
|
1,926,654 |
|
Accumulated other comprehensive gain |
|
72 |
|
|
|
14 |
|
Accumulated deficit |
|
(2,207,100 |
) |
|
|
(2,078,360 |
) |
TOTAL STOCKHOLDERS’ DEFICIT |
|
(163,030 |
) |
|
|
(151,604 |
) |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
$ |
461,564 |
|
|
$ |
478,454 |
|
REVANCE THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) |
|||||||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenue: |
|
|
|
|
|
|
|
||||||||
Product revenue, net |
$ |
58,827 |
|
|
$ |
54,109 |
|
|
$ |
175,874 |
|
|
$ |
154,160 |
|
Collaboration revenue |
|
1,052 |
|
|
|
3 |
|
|
|
1,330 |
|
|
|
139 |
|
Total revenue, net |
|
59,879 |
|
|
|
54,112 |
|
|
|
177,204 |
|
|
|
154,299 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of product revenue (exclusive of amortization) |
|
17,633 |
|
|
|
16,821 |
|
|
|
50,179 |
|
|
|
46,915 |
|
Selling, general and administrative |
|
62,578 |
|
|
|
65,791 |
|
|
|
197,314 |
|
|
|
202,523 |
|
Research and development |
|
11,379 |
|
|
|
8,688 |
|
|
|
41,674 |
|
|
|
43,844 |
|
Amortization |
|
545 |
|
|
|
374 |
|
|
|
1,636 |
|
|
|
1,636 |
|
Total operating expenses |
|
92,135 |
|
|
|
91,674 |
|
|
|
290,803 |
|
|
|
294,918 |
|
Loss from continuing operations |
|
(32,256 |
) |
|
|
(37,562 |
) |
|
|
(113,599 |
) |
|
|
(140,619 |
) |
Interest income |
|
2,631 |
|
|
|
3,733 |
|
|
|
8,806 |
|
|
|
9,851 |
|
Interest expense |
|
(6,732 |
) |
|
|
(5,093 |
) |
|
|
(17,667 |
) |
|
|
(13,958 |
) |
Other expense, net |
|
(258 |
) |
|
|
(223 |
) |
|
|
(1,149 |
) |
|
|
(1,056 |
) |
Loss from continuing operations before income taxes |
|
(36,615 |
) |
|
|
(39,145 |
) |
|
|
(37,469 |
) |
|
|
(58,166 |
) |
Income tax provision |
|
(1,500 |
) |
|
|
(300 |
) |
|
|
(1,500 |
) |
|
|
(300 |
) |
Net loss from continuing operations |
|
(38,115 |
) |
|
|
(39,445 |
) |
|
|
(125,109 |
) |
|
|
(146,082 |
) |
Net loss from discontinued operations |
|
— |
|
|
|
(101,731 |
) |
|
|
(3,631 |
) |
|
|
(122,205 |
) |
Total net loss |
|
(38,115 |
) |
|
|
(141,176 |
) |
|
|
(128,740 |
) |
|
|
(268,287 |
) |
Unrealized gain |
|
98 |
|
|
|
48 |
|
|
|
58 |
|
|
|
361 |
|
Comprehensive loss |
$ |
(38,017 |
) |
|
$ |
(141,128 |
) |
|
$ |
(128,682 |
) |
|
$ |
(267,926 |
) |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted net loss per share: |
|
|
|
|
|
|
|
||||||||
Continuing operations |
$ |
(0.37 |
) |
|
$ |
(0.46 |
) |
|
$ |
(1.25 |
) |
|
$ |
(1.74 |
) |
Discontinued operations |
|
— |
|
|
|
(1.17 |
) |
|
|
(0.04 |
) |
|
|
(1.46 |
) |
Total net loss per basic and diluted share |
$ |
(0.37 |
) |
|
$ |
(1.63 |
) |
|
$ |
(1.29 |
) |
|
$ |
(3.20 |
) |
|
|
|
|
|
|
|
|
||||||||
Basic and diluted weighted-average number of shares used in computing net loss per share |
|
104,212,891 |
|
|
|
86,613,425 |
|
|
|
100,016,088 |
|
|
|
83,816,577 |
|
REVANCE THERAPEUTICS, INC. |
|||||||||||
Product Revenue Breakdown (Unaudited) |
|||||||||||
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||||||
(in thousands) |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
Product: |
|
|
|
|
|
|
|
||||
RHA® Collection of dermal fillers |
$ |
30,503 |
|
$ |
32,133 |
|
$ |
96,704 |
|
$ |
94,180 |
DAXXIFY® |
|
28,324 |
|
|
21,976 |
|
|
79,170 |
|
|
59,980 |
Total product revenue, net |
$ |
58,827 |
|
$ |
54,109 |
|
$ |
175,874 |
|
$ |
154,160 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107685733/en/
Investors
Laurence Watts,
New Street Investor Relations
laurence@newstreetir.com
Media
Revance@evolvemkd.com
Source: Revance Therapeutics, Inc.
FAQ
What were Revance's Q3 2024 financial results?
What is the status of the merger between Revance and Crown Laboratories?
What new distribution agreements did Revance announce?
Has DAXXIFY been approved in any new markets?